Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
Ruxolitinib 1.5% Cream BID
DRUG
3 trials
Sponsors
Incyte Corporation
, Peking University Third Hospital
, The Children's Hospital of Zhejiang University School of Medicine
Conditions
Atopic Dermatitis
Vitiligo
Phase 2
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Phosphate Cream Applied Topically to Adults With Atopic Dermatitis
Completed
NCT03011892
Incyte Corporation
Atopic Dermatitis
Start: 2017-01-09
End: 2018-03-12
Updated: 2021-04-09
Phase 3
Efficacy and Safety of Ruxolitinib Cream in Chinese Children Aged 2-11 Years With Non-segmental Vitiligo
Not yet recruiting
NCT07595939
The Children's Hospital of Zhejiang University School of Medicine
Vitiligo
Start: 2026-06-01
End: 2028-12-31
Target: 20
Updated: 2026-05-19
Unknown Phase
A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
Recruiting
NCT07153666
Peking University Third Hospital
Vitiligo
Start: 2025-12-08
End: 2027-12-31
Target: 170
Updated: 2026-01-02
Related Papers
Pharmacokinetics of Ruxolitinib in Patients with Atopic Dermatitis Treated With Ruxolitinib Cream: Data from Phase II and III Studies.
2021-05-12
47 citations
Ruxolitinib Cream Has Dual Efficacy on Pruritus and Inflammation in Experimental Dermatitis
Frontiers in Immunology
2021-02-15
20 citations
Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream.
2019-10-17
162 citations